A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Human Epithelial Receptor (HER)-2 Positive Breast Cancer
Interventions: DRUG: Trastuzumab|DRUG: Paclitaxel
Sponsor: Biocad